Celiprolol therapy for vascular Ehlers-Danlos syndrome

Lancet. 2010 Oct 30;376(9751):1443-4. doi: 10.1016/S0140-6736(10)61155-5. Epub 2010 Sep 7.

Author

Benjamin S Brooke¹

Affiliation

¹ Department of Surgery, Johns Hopkins Hospital, Baltimore, MD 21287, USA. bbrooke1@jhmi.edu

PMID: 20825985
DOI: 10.1016/S0140-6736(10)61155-5

No abstract available

Publication types

Comment

MeSH terms

Adrenergic beta-Agonists / therapeutic use*
Adrenergic beta-Antagonists / therapeutic use*
Aneurysm, Ruptured / etiology
Aneurysm, Ruptured / prevention & control
Aortic Dissection / etiology
Aortic Dissection / prevention & control
Celiprolol / therapeutic use*
Ehlers-Danlos Syndrome / complications*
Ehlers-Danlos Syndrome / genetics
Ehlers-Danlos Syndrome / metabolism
Humans
Signal Transduction
Transforming Growth Factor beta / genetics
Transforming Growth Factor beta / metabolism
Vascular Diseases / etiology
Vascular Diseases / prevention & control*

Substances

Adrenergic beta-Agonists
Adrenergic beta-Antagonists
Transforming Growth Factor beta
Celiprolol